Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Darin K Edwards

Showing results (11-20 of 54) with videos related to

Pageof 6
Sort By:
Nature Medicine|March 4, 2022
Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trialLaurence Chu, Keith Vrbicky, David Montefiori, et al.
Biorxiv : the Preprint Server for Biology|January 27, 2021
mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variantsKai Wu, Anne P Werner, Juan I Moliva, et al.
Frontiers in Immunology|April 2, 2024
Profiling antibody epitopes induced by mRNA-1273 vaccination and boostersBethany Girard, Elisabeth Baum-Jones, Rebecca L Best, et al.
Biorxiv : the Preprint Server for Biology|January 31, 2024
Intestinal helminth infection impairs vaccine-induced T cell responses and protection against SARS-CoV-2Pritesh Desai, Courtney E Karl, Baoling Ying, et al.
Science Translational Medicine|August 21, 2024
Intestinal helminth infection impairs vaccine-induced T cell responses and protection against SARS-CoV-2 in micePritesh Desai, Courtney E Karl, Baoling Ying, et al.
The Journal of Infectious Diseases|February 13, 2024
Interim Report of the Reactogenicity and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 XBB-Containing VaccinesSpyros Chalkias, Nichole McGhee, Jordan L Whatley, et al.
Nature Medicine|October 6, 2022
Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trialSpyros Chalkias, Frank Eder, Brandon Essink, et al.
Nature Communications|August 23, 2023
Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19Spyros Chalkias, Charles Harper, Keith Vrbicky, et al.
The New England Journal of Medicine|September 16, 2022
A Bivalent Omicron-Containing Booster Vaccine against Covid-19Spyros Chalkias, Charles Harper, Keith Vrbicky, et al.
Med (New York, N.Y.)|May 18, 2022
mRNA-1273 and Ad26.COV2.S vaccines protect against the B.1.621 variant of SARS-CoV-2Tamarand L Darling, Baoling Ying, Bradley Whitener, et al.
Pageof 6

Showing results (11-20 of 54) with videos related to

Sort By:
Pageof 6
Nature Medicine|March 4, 2022
Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trialLaurence Chu, Keith Vrbicky, David Montefiori, et al.
Biorxiv : the Preprint Server for Biology|January 27, 2021
mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variantsKai Wu, Anne P Werner, Juan I Moliva, et al.
Frontiers in Immunology|April 2, 2024
Profiling antibody epitopes induced by mRNA-1273 vaccination and boostersBethany Girard, Elisabeth Baum-Jones, Rebecca L Best, et al.
Biorxiv : the Preprint Server for Biology|January 31, 2024
Intestinal helminth infection impairs vaccine-induced T cell responses and protection against SARS-CoV-2Pritesh Desai, Courtney E Karl, Baoling Ying, et al.
Science Translational Medicine|August 21, 2024
Intestinal helminth infection impairs vaccine-induced T cell responses and protection against SARS-CoV-2 in micePritesh Desai, Courtney E Karl, Baoling Ying, et al.
The Journal of Infectious Diseases|February 13, 2024
Interim Report of the Reactogenicity and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 XBB-Containing VaccinesSpyros Chalkias, Nichole McGhee, Jordan L Whatley, et al.
Nature Medicine|October 6, 2022
Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trialSpyros Chalkias, Frank Eder, Brandon Essink, et al.
Nature Communications|August 23, 2023
Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19Spyros Chalkias, Charles Harper, Keith Vrbicky, et al.
The New England Journal of Medicine|September 16, 2022
A Bivalent Omicron-Containing Booster Vaccine against Covid-19Spyros Chalkias, Charles Harper, Keith Vrbicky, et al.
Med (New York, N.Y.)|May 18, 2022
mRNA-1273 and Ad26.COV2.S vaccines protect against the B.1.621 variant of SARS-CoV-2Tamarand L Darling, Baoling Ying, Bradley Whitener, et al.
Pageof 6